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Pulmonary embolism (PE) is a thrombotic emergency and can be life-threatening, with an estimated incidence of > 600,000 patients annually. As the third leading cause of cardiovascular mortality following myocardial infarction and stroke, PE is responsible for approximately 200,000 deaths yearly 1, 2 .
Various risk stratification algorithms may be utilized to determine short-term mortality following PE. The Pulmonary Embolism Severity Index (PESI) is one such algorithm used widely for predicting 30-day mortality in patients diagnosed with acute but relatively low risk PE [3] [4] [5] [6] . The PESI score is based on clinical variables including: sex, age, heart failure, chronic lung disease, altered mental status and malignancy as well as the patient vital signs: respiratory rate, heart rate, oxygen saturation, temperature, and systolic blood pressure < 100 mm Hg 3, 7 (Supplemental Figure 1) . The BOVA score is also reported to predict 30-day mortality. The BOVA score is designed for use in normotensive patients but incorporates some higher risk clinical features: systolic blood pressure < 100 mm Hg, heart rate > 100 beats/min, elevated cardiac troponin (cTnT), and the presence of right ventricle (RV) dysfunction by imaging 8 (Supplemental Figure 2) .
RV dysfunction appears to be an independent variable predicting mortality attributable to PE 9 . The presence of RV dysfunction may increase short-term mortality by greater than two-fold in the context of acute PE 10, 11 . RV dysfunction may be directly determined qualitatively and quantitatively by various imaging modalities, or inferred elevated using cardiac biomarkers as a surrogate. Whilst the American College of Chest physicians (ACCP) does not endorse routine assessment of plasma cardiac biomarkers in every patient diagnosed with PE, the European Society of Cardiology (ESC) guidelines include the PESI score as well as cardiac biomarkers as well as cardiac imaging information to further risk stratify a patient with acute PE [12] [13] [14] . Recent studies suggest that elevated plasma cardiac troponin in patients with PE is associated with an increase in all-cause mortality 12 .
The use of Pulmonary Embolism Response Teams (PERTs) to rapidly assess patient risk and to institute a treatment algorithm for patients with submassive and massive PE has gained popularity around the world, and may improve both mortality and the efficiency of treatment in acute care environments such as the emergency department [15] [16] [17] [18] curve data were reported as the area under the curve (AUC), along with sensitivity and specificity and biomarker concentration cut-points. It is important to note that the ROC curves used for categorically assigned classes of PE were based on RV dysfunction by imaging which allowed us to fairly assess the predictive ability of cardiac biomarkers in acute PE. Dichotomous variables are presented as frequencies and continuous variables as mean with standard error of mean (SEM) unless otherwise stated. The distribution of data was interrogated for normality using the Shapiro-Wilk test before comparison between groups. For data that were not Gaussian-distributed, the Mann-Whitney U test was used when comparing two groups, and the Kruskal-Wallis test followed by Dunn post-test was used for three or more group comparisons. For Gaussian-distributed data, the student's t-test was used to compare two groups and, for three or more group comparisons, 1-way ANOVA then the Bonferroni multiple comparisons test was used.
Significance was determined if the P value was < 0.05. All data were analyzed with GraphPad Prism 7 (GraphPad Software, Inc, La Jolla, CA).
Results

Study Population
571 patient charts were reviewed, 286 of which were determined to be clinical presentations of acute PE. Patients were excluded following chart review if a primary diagnosis other than PE was determined, if the diagnosis was made at another institution, or if the patient had only a history of VTE/PE ( Figure. 1 ). The demographic variables and observed short-term outcomes for the patient population are shown in Table 1 .
Plasma Cardiac Biomarker Concentration in patients with acute PE according to PESI
Class or Categorical Assignment
We used imaging data to determine the presence of RV dysfunction. We then examined categorical assignment of PE severity, observing a stepwise increase in plasma cTnT and NT-proBNP from low risk PE to massive PE. Conversely, using the PESI scoring system, an upward trend in plasma cardiac biomarker concentration was not clearly observed with ascending PESI class ( Figure 2 ).
Performance of Cardiac Biomarkers in patients with acute PE for distinguishing between PESI Class compared to Categorical Assignment
Based on the ROC analysis of cardiac biomarkers in patients with RV dysfunction determined purely by imaging, cTnT distinguished between low risk PE and submassive Using the categorical classification of low risk, submassive, or massive PE, the mean calculated PESI scores trended in an ascending manner. However, when attempting to determine a PESI score cut-point by ROC curve analysis, the value obtained to distinguish low risk from submassive PE was 93 (30 day predicted mortality of 4.8%, Figure. 5 ) which was 1.8-fold lower than the observed mortality (Table 1) .
Similarly, the predicted PESI score cut point to distinguish low risk PE from massive PE by ROC curve analysis was 108 (30 day predicted mortality of 4.8%) which was 7.2-fold lower than the observed mortality for massive PE (Table 1) .
Performance of Cardiac Biomarkers in patients with acute PE for distinguishing between BOVA stages compared to Categorical Assignment
Whilst the BOVA score was validated as a short-term predictor of mortality in patients with normotensive (low risk and submassive) acute PE 8 , components of BOVA (Supplemental Figure 2 ) do include certain high-risk features such as RV dysfunction and elevation of a plasma biomarker of myocardial necrosis. In spite of these features of BOVA, all BOVA stages showed markedly lower plasma cTnT concentration compared to patients who were stratified into the submassive PE category in each BOVA stage based only on radiographic evidence of RV dysfunction. Furthermore, assessing the BOVA score for each patient with low risk PE compared to submassive PE, ROC curve analysis revealed a BOVA stage cut-point predicting a 30-day mortality of 3.1%, which was 2.7-fold lower than the observed mortality in our patients with submassive PE (Table   1) Together, these data imply that a biomarker of myocardial strain, a biomarker of myocardial necrosis, and the presence of RV dysfunction radiographically-with or without sustained hypotension-in submassive and massive PE, respectively, provide more accurate information for patient mortality risk not accounted for by the PESI or the BOVA score.
Discussion
According to published registries, the average 3-month mortality for a patient with submassive PE is 20-25% and 50-60% for a patient with massive PE 20 . Therefore, the presence of RV dysfunction or sustained hypotension are simple and more relevant clinical variables to rapidly determine patient risk irrespective of whether a hospital utilizes the PERT concept to assist in immediate risk stratification. Our investigation has several limitations. Consistent with previous studies of patients with acute PE in whom RV dysfunction was documented, there is a subjective component to this interpretation, particularly when echocardiography is the imaging modality utilized. In addition, while a measured RV/LV ratio > 0.9 in the apical 4 chamber view on either CTA or echocardiography suggests RV dilation, volume status, and chronic medical conditions such as obesity, pulmonary hypertension, and right-sided valvular insufficiency all augment RV loading conditions. Therefore, any cause of increased contrast noted in the pulmonary vasculature and RV by CTA is subject to being interpreted as evidence on "RV dysfunction", as reported 20, 32-34 . Our study also excluded patients with a pre-existing diagnosis of VTE/PE, or patients with diagnosis of acute PE at an outside facility who were later transferred in to our institution. These factors limit external validity.
Conclusions
Using cardiac biomarkers as a surrogate for RV dysfunction, which was determined separately by imaging or sustained hypotension, we found that the PESI and BOVA scoring systems underestimate a patient's true short-term mortality risk in the clinical context of acute PE. We therefore suggest that when a rapid decision is required to assess patient risk or to select a treatment plan in the context of acute PE-which is the nature of a PERT-the presence of RV dysfunction and elevated cardiac biomarkers are the most relevant clinical variables determining short term mortality. TnT levels by Category • Cancer + 30
• Heart failure + 10
• COPD + 10
• HR ≥ 110 bmp + 20
• SBP < 100 mmHg + 30
• RR ≥ 30 + 20
• BT < 36 °C + 20
• Delirium + 60 
Clinical Variables Points
• SBP < 100 mm Hg 2
• Heart Rate > 100 beats/minute 1
• Elevated Cardiac Troponin 2
• RV Dysfunction by Imaging 2
Criteria for Right Ventricular Dysfunction
Echocardiography Computed Tomography
• RV / LV EDD > 0.9 in apical four chamber view
• RV to LV diameter ratio > 0.9
• RV EDD > 30 mm and/or loss of inspiratory collapse of the inferior vena cava
• McConnell sign (hypokinesis of RV free wall and base with hyperkinetic RV apex)
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